© 2025 MJH Life Sciences™ , Patient Care Online – Primary Care News and Clinical Resources. All rights reserved.
Grace Halsey
Articles
Novel Nonopioid Dual Action Analgesic Highly Effective Against Post-Surgical Pain in Phase 2b Trial
January 02, 2025
The new chemical entity from Xgene Pharmaceuticals, XG005, targets both anti-nociceptive and anti-neuropathic pain pathways.
For Alzheimer Agitation, a Novel, Oral NMDA Inhibitor Could be the Next Targeted Treatment
January 02, 2025
Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.
Axsome Completes Phase 3 Clinical Program with AXS-05 in Alzheimer Disease Agitation
January 02, 2025
Axsome plans to submit a New Drug Application to the FDA in the second half of 2025 that is based on positive results from 4 pivotal phase 3 clinical trails and long-term data.
US Adolescent Substance Use Holding Steady or Declining: Highlights from the 2024 Monitoring the Future Survey
January 02, 2025
Substances of choice used in the previous 12 months were alcohol, nicotine vaping, and cannabis but the trends among the 8th, 10th, and 12th graders are very encouraging.
FDA Adds Black Box Warning to Fezolinetant Label, Advising of Rare but Serious Liver Injury
December 23, 2024
The black box warning, the agency's most prominent alert, follows earlier additions to the original fezolinetant label about hepatic injury and regular LFT testing.
Crinecerfont for Congenital Adrenal Hyperplasia Now Commercially Available, Neurocrine Biosciences Announces
December 20, 2024
The first in class CRF-1 receptor antagonist allows people with CAH to reduce glucocorticoid doses while androgen levels are maintained or improved.
CagriSema Leads to Weight Reduction of Approximately 23% in Phase 3 REDEFINE 1 Clinical Trial, Short of the 25% Expected
December 20, 2024
The 22.7% weight loss at 68 weeks places CagriSema essentially on par with, not superior to, competing antiobesity drugs including Lilly's tirzepatide.
Women are at Higher Genetic Risk for PTSD than Men, According to Large Twin-Sibling Study
December 19, 2024
In the largest twin-sibling study to date of the inherited biological risk of PTSD, researchers found additive genetic and unique environmental effects contributed to the disorder.
Vertex Nonopioid Analgesic on Par with Placebo in Phase 2 Study of Lumbosacral Radiculopathy
December 19, 2024
Pain relief with suzetrigine was comparable to that seen with placebo, an issue Vertex plans to address with study design as the drug moves to the pivotal phase 3 trials.
Vaccination Information and Educational Resources from the National Foundation for Infectious Diseases
December 19, 2024
Robert Hopkins, Jr, MD, NFID medical director, details a range of resources on the foundation's website including in-depth vaccine recommendations, live webinars, plus much more.